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Crystal structure of a low molecular 
weight activator Blm-pep with 
yeast 20S proteasome – insights 
into the enzyme activation 
mechanism
Julia Witkowska1, Małgorzata Giżyńska1, Przemysław Grudnik2,3, Przemysław Golik2,3, 
Przemysław Karpowicz1, Artur Giełdoń1, Grzegorz Dubin  2,3 & Elżbieta Jankowska  1
Proteasomes are responsible for protein turnover in eukaryotic cells, degrading short-lived species 
but also removing improperly folded or oxidatively damaged ones. Dysfunction of a proteasome 
results in gradual accumulation of misfolded/damaged proteins, leading to their aggregation. It 
has been postulated that proteasome activators may facilitate removal of such aggregation-prone 
proteins and thus prevent development of neurodegenerative disorders. However, the discovery of 
pharmacologically relevant compounds is hindered by insufficient structural understanding of the 
activation process. In this study we provide a model peptidic activator of human proteasome and 
analyze the structure-activity relationship within this novel scaffold. The binding mode of the activator 
at the relevant pocket within the proteasome has been determined by X-ray crystallography. This 
crystal structure provides an important basis for rational design of pharmacological compounds. 
Moreover, by providing a novel insight into the proteasome gating mechanism, our results allow the 
commonly accepted model of proteasome regulation to be revisited.
The ubiquitin-proteasome system (UPS) is responsible for degradation of the majority of cytosolic proteins. The 
central element of this system, 26S proteasome, is composed of a multicatalytic 20S core particle (CP) and a 19S 
regulator. The role of the latter is to remove degradation marks (deubiquitination) and to unfold the proteins 
designated for proteolysis within the CP. The eukaryotic CP is a barrel-shaped structure composed of four stacked 
heptameric rings, each consisting of seven different subunits of either α- or β-type, arranged in the αββα fashion1, 2. 
The luminal chamber formed by these rings accommodates six active sites of three different proteolytic activ-
ities: peptidylglutamyl peptide hydrolyzing (PGPH) (β1/β1′ subunits), trypsin-like (T-L; β2/β2′ subunits), and 
chymotrypsin-like (ChT-L; β5/β5′ subunits) peptidases.
In the latent 20S proteasome, access of polypeptides to the catalytic chamber is restricted by the N-termini of 
the α subunits, which form a kind of a gate3. Apart from ATP-dependent 19S regulators (PAN in Archaea), two 
additional classes of activating proteins may facilitate passage of substrates to the proteasome interior: 11S (also 
known as PA28 in higher eukaryotes and PA26 in Trypanosoma brucei) and Blm10/PA200 (Saccharomyces cere-
visiae/human). It is postulated that all activating particles display a common mechanism of action which involves 
anchoring at the proteasome surface and repositioning of the Pro17 reverse turn. This activator binding-induced 
shift of the Pro17 position results in reorganization of the N-termini of the α subunits, enabling substrate access 
into the catalytic chamber4.
There are only three proteinaceous ligands whose crystal structures in the complex with proteasome are 
known so far: – Blm10, Pba1-Pba2, and PA26. The first two proteins anchor to proteasome using their C-terminal 
HbYX motif (Hb – hydrophobic residue, Y – tyrosine, X – any residue), whose binding is believed to enable 
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repositioning of the Pro17 reverse turn and cause the gate opening. Activation by PA26 requires involvement 
of two regions: the C-terminal one, deficient of the HbYX motif, is needed for binding to proteasome, while the 
so-called activation loop is responsible for the Pro17 shift and opening the entrance to the catalytic chamber5. 
PA26 is a heptameric protein and as such may create contacts with multiple intersubunit pockets: the electron 
density of the C-termini of PA26 has been detected in α2/α3, α3/α4, α4/α5, and α5/α6 pockets in complexes 
with yeast and archeal proteasomes6. Monomeric Blm10 interacts exclusively with only one, the α5/α6 pocket4. 
Its C-terminal carboxylate forms a salt bridge with the conserved α6Lys62 (equivalent to Lys66 in archeal protea-
some) whereas a side chain of the penultimate tyrosine interacts with α5Gly19, prompting translocation of the 
α5Pro17 reverse turn. Such an interaction significantly affects only a single α subunit and thus the entrance pore 
in Blm10-20S complex is only partially open4, 7. In multimeric activators, like PA26, binding affects multiple α 
subunits resulting in wider opening of the entrance gate8.
Quite recent cryo-EM structures of human and yeast 26S proteasomes revealed some details about the inter-
actions of the catalytic 20S core and 19S regulator9–12. Three subunits of 19S, namely Rpt2, Rpt3 and Rpt5, possess 
the HbYX motif. In human 26S two of them – Rpt3 and Rpt5 – were found to bind in the proteasome intersubunit 
pockets, Rpt3 in α1/α2 and Rpt5 in α5/α69, 11. Nevertheless, the gate leading to the catalytic chamber remained 
closed in this structure. A similar situation was observed in the case of y26S, where binding of three subunits with 
the HbYX moiety did not trigger the gate opening10, 12. The open conformation was observed, however, in one 
conformational state of y26S, in which the fourth subunit – Rpt6 – was bound within the proteasome α ring12. 
The other known examples of the proteasome with the gate open are crystal structures of complexes of archea-
bacterial 20S with mutated PA26. In these constructs either (i) seven or eight residues of the C-terminal sequence 
of PA26 were substituted with the sequence of PAN’s C-terminus, holding the conserved HbYX motif (PDB: 
3JTL/3IPM, respectively)8, 13; or (ii) only the penultimate Val residue of PA26 was exchanged into Phe (PDB: 3JSE) 
or Tyr (PDB: 3JRM)8. In all these structures multiple contacts of the binding motifs with the proteasome inter-
subunit pockets were observed, resulting in the displacement of all seven Pro17 clusters and the gate opening.
The proteasome plays an important role in numerous homeostatic and regulatory processes, including cell 
cycle progression, growth and atrophy of tissues, and oncogenesis14–16. By degrading mutated, misfolded or oxi-
datively damaged proteins the proteasome is involved also in cellular quality control17. Defects in proteasome 
function play an important role in the pathophysiology of a number of disorders, including inflammation, auto-
immune and neurodegenerative diseases, and various cancers. Its broad implication in pathological processes 
makes the proteasome a suitable target for pharmacological intervention. Many competitive small-molecule 
inhibitors of the proteasome have been developed, and three have been approved by the FDA for use in blood can-
cer treatment: bortezomib, carfilzomib and ixazomib18, 19. In contrast, development of proteasome activators has 
been almost neglected, mainly because of a poor understanding of the underlying mechanisms, including a lack 
of structural explanation and definition of binding sites. It was only recently that stimulation of the proteasome 
was proposed in management of Parkinson’s and Huntington’s diseases20, 21 and oxidative stress consequences22–24. 
To facilitate progress in this field, in this study we have focused on characterization of a new proteasome activator: 
Blm-pep. It is a 14-residue peptide, which can be a starting point for bioisosteric replacements providing more 
stable and efficient activators. We designed this compound based on mechanistic features of the Blm10 protein. 
The significance of particular segments of Blm-pep in its ability to activate human ChT-L, T-L and PGPH pepti-
dases has been evaluated using a number of analogs. A crystal structure of Blm-pep in a complex with yeast pro-
teasome has been obtained and revealed a closed conformation of the enzyme entrance pore, which is consistent 
with the lack of activity of Blm-pep against y20S. A molecular dynamics simulation was undertaken to explain 
the observed different capacity of Blm-pep to activate orthologous human and yeast proteasomes. The obtained 
results allow us to propose corrections to the currently established model of the proteasome gating mechanism.
Methods
Synthesis of Blm peptides. The peptides were synthesized on either TentaGel R PHB or Wang resin (load-
ing capacity of 0.2 or 0.35 mmol/g, respectively). Syntheses were performed using a Microwave Liberty Blue 
synthesizer (CEM) or Millipore model 9050 Plus peptide synthesizer. The first amino acid was attached to the 
resin using a symmetrical anhydride or 1-(2-mesitylenesulfonyl)-3-nitro-1H-1,2,4-triazole/1-methylimida-
zole method, and the coupling efficiency was determined by measurement of absorbance of the resulting ful-
vene-piperidine adduct, at λ = 301 nm. Subsequent residues were added using standard Fmoc/tBu chemistry. 
Crude peptides were purified to at least 98% purity by reversed-phase high-performance liquid chromatography 
(RP-HPLC) using a Jupiter Proteo column (21.2 × 250 mm, 4 μm, 90 Å; Phenomenex). A linear gradient of ace-
tonitrile in 0.1% aqueous trifluoroacetic acid (TFA) or acetonitrile in 0.1 M triethylamine phosphate buffer, pH 
3.0, was used as a mobile phase. The purity of the synthesized compounds was evaluated by analytical RP-HPLC 
using a XB-C18 Aeris Peptide column (4.6 × 150 mm, 3.6 μm, 100 Å, Phenomenex) and a 30 min linear gradient 
of 5–80% acetonitrile in 0.1% aqueous TFA. UV absorption was monitored at λ = 223 nm. The molecular weight 
of the peptides was confirmed by matrix-assisted laser desorption/ionization time-of-flight (MALDI TOF) mass 
spectrometry or electrospray ionization ion trap time-of-flight liquid chromatography mass spectrometry (ESI 
IT TOF LCMS) with a C12 Jupiter Proteo column (150 × 2 mm, 4μm, 90 Å; Phenomenex). MS data are listed in 
Supplementary Table 1S.
Proteasome activity assays. The influence of the peptides on the catalytic activities of the 
20S proteasome was tested using latent housekeeping CP isolated from either human erythrocytes 
or yeast cells (Enzo Life Sciences). The CP was utilized at a final concentration of 2 nM. The follow-
ing fluorogenic peptide substrates were employed to determine the activity of proteasomal peptidases: 
succinyl-Leu-Leu-Val-Tyr-4-methylcoumarin-7-amide (Suc-LLVY-MCA, for determination of ChT-L activ-
ity), tert-butyloxycarbonyl-Leu-Arg-Arg-4-methylcoumarin-7-amide (Boc-LRR-MCA, for T-L activity), and 
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carbobenzoxy-Leu-Leu-Glu-4-methylcoumarin-7-amide (Z-LLE-MCA, for PGPH activity). Stock solutions of 
the substrates and the tested peptides were prepared in dimethyl sulfoxide (DMSO). To minimize any unspecific 
effect of DMSO its concentration was kept below 3% of the final reaction volume. All assays were performed at 
37 °C in the 96-well plate format using a reaction volume of 100 μl. Tests were carried out in 50 mM Tris-HCl 
(pH 8.0, measured at 20 °C). The peptides were tested in the concentration range of 0.05–10 μM. Substrates were 
added at 100 μM final concentration. The release of aminomethylcoumarin (AMC) was monitored continuously 
for 60 min by measuring fluorescence at 460 nm (Infinite 200 PRO, TECAN) at 2-min intervals. All activity assays 
were performed at least in triplicate, each as an independent measurement, utilizing separate aliquots of the mod-
ulator, substrate and enzyme stock solutions. The peptidolytic activity was calculated as nanomoles of the released 
AMC product per milligram of CP per second. In the case of the control this value was regarded as 100% activity 
of the latent proteasome. Values for the tested compounds were determined in an identical way and calculated as 
a percentage of the control.
Proteolytic stability assay. Blm-pep was incubated either with human or yeast 20S proteasome. Both 
assays were conducted in 25 mM Tris-HCl buffer (pH 8.0, measured at 20 °C), which for y20S contained 0.25 mM 
EDTA as an additive. The peptide and proteasome concentrations in 100 μl final solution were 10 µM and 
0.025 mg/ml, respectively. Incubation was carried out for 3 hours at 37 °C. The reaction was stopped by addition 
of 5 μl of 10% TFA. Results were analyzed using RP-HPLC and MALDI TOF. Prior to MS analysis the samples 
were desalted using C18 spin columns (Pierce).
Isolation and purification of the yeast 20S proteasome. For crystallization experiments, 20S 
proteasome was isolated from Saccharomyces cerevisiae (strain MHY501) according to previously pub-
lished protocols25–27. In brief, S. cerevisiae were cultured in YPD (1% yeast extract, 2% peptone, 2% glucose) 
to OD600nm > 1. Cells were collected by centrifugation and lysed in a continuous cell disruption system in lysis 
buffer (50 mM Tris-HCl pH 7.5, 250 mM sucrose, 1 mM DTT). The lysate was clarified by centrifugation and the 
proteasome-containing fraction was recovered by centrifugation at 120 000 x g. The pellet was resuspended in 
50 mM Tris-HCl pH 7.5 containing 20% of glycerol and applied to a Pierce Strong Anion Exchange Spin Column 
(29.7 × 122 mm, Thermo Scientific). The column was washed with a step gradient of NaCl (up to 2 M), and 
the proteasome eluted at 400 mM NaCl. The protein content in the collected fractions was verified based on 
activity tests against the proteasome ChT-L substrate. Active fractions were pooled and further purified using a 
hydroxyapatite type II column (CHT type II, Bio Rad) with increasing phosphate gradient (Na2HPO4/NaH2PO4 
pH 7.5, 20% glycerol). The proteasome eluted at approximately 220 mM phosphate buffer. The final polishing step 
consisted of gel filtration on Superose 6 in 50 mM Tris/HCl pH 7.5.
Crystallization. Just prior to crystallization, 20S proteasome was concentrated to 2.5–5 mg/ml using Amicon 
Ultra 100 K centrifugal concentrators (Merck Millipore). Crystals were grown by the hanging drop vapor dif-
fusion method at 20 °C, as previously described28. Drops were prepared by adding 0.5 µl of protein stock, 0.4 µl 
of reservoir solution (35 mM magnesium acetate, 13% MPD, 0.1 M MES pH 6.5) and 0.1 µl of 4% DMSO as an 
additive. Crystals appeared within 7 days and continued to grow for about two weeks. The preformed crystals 
were soaked for 24 hours with Blm-pep (0.5 µM) and flash frozen after cryoprotection in 25% ethylene glycol in 
the mother liquor.
Structure determination and refinement. Diffraction data were collected at 100 K at the 14.1 beam-
line at the Helmholtz Zentrum in Berlin, Germany. The data was indexed and integrated using XDS29, 30 and 
scaled using the SCALA program contained in the CCP4 package31. The crystal structure was determined by 
molecular replacement using MOLREP32 and coordinates of the apo 20S yeast proteasome (PDB ID: 1RYP) as a 
search model. Initial refinement was performed using Refmac 5.02433 while Phenix34 was used in the later stages. 
Torsion-angle noncrystallographic symmetry (NCS) averaging was applied. Five percent of reflections were used 
for the cross-validation analysis and the progress of refinement was monitored using the Rfree parameter35. The 
model was constructed in Coot36. Blm-pep ligand was introduced at the final stages of refinement into the clearly 
defined electron density. The quality of the final structure was assessed using a MolProbity server37. Data col-
lection and refinement statistics are summarized in Table 2S. The structure was deposited at the Protein Data 
Bank (PDB ID: 5NIF). The final models were analysed and figures were prepared using Coot and PyMol (Delano 
Scientific, USA).
Molecular modeling. Structures of human constitutive 20S proteasome (PDB ID: 4R3O) and yeast 20S 
proteasome in complex with Blm-pep determined in this study (PDB ID: 5NIF) were used in modeling. The 
C-terminal HbYX motif anchors Blm-pep between the α5 and α6 subunits of yeast proteasome, and it was mod-
eled in the same place for the human counterpart. To obtain the lowest energy structure the model was mini-
mized (500 cycles) and optimized by short, low temperature (2 ps, 50 K) molecular dynamics in repetitive cycles 
using the AMBER v.12 package38. This procedure allowed the constructed model to correspond to the experi-
mental data to the maximum possible extent. The model of Blm-pep binding to human proteasome was analyzed 
using the RasMol AB program39.
Results
Design of Blm-pep activator. Blm-pep (KYFTGSKLWRSYYA) was designed based on the Blm10 activator 
of 20S proteasome and other prior data. To provide an anchor at the α subunit surface of the proteasome we used 
a sequence derived from the C-terminus of Blm10 (LWRSYYA), which provides such interactions. Our earlier 
studies40, 41 revealed the importance of basic amino acids for proteasome allosteric modulation and therefore we 
incorporated two lysine residues into the design of Blm-pep. Tyrosine and phenylalanine residues were further 
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incorporated into Blm-pep with the intention of providing aromatic contacts with the N-termini of the α subu-
nits, which we believed are important in the mechanism of proteasome gate opening (for a more detailed expla-
nation of the basis of Blm-pep design, see Supplementary information). A polar linker (TGS) was additionally 
added to improve solubility and elongate the peptide to allow concomitant anchoring at the intersubunit pocket 
and interactions with the residues surrounding the entrance to the catalytic channel.
Proteolytic stability of Blm-pep. A proteolytic stability assay revealed that Blm-pep is digested by both 
human and yeast 20S proteasome (Supplementary Information, Fig. 1S). To determine cleavage sites, digestion 
reactions were analyzed by mass spectrometry. Some differences between the degradation patterns of yeast and 
human proteasomes were spotted, although they were not significant.
Activity of Blm-pep and delimitation of the active fragment. Activity assays demonstrated 
that Blm-pep efficiently stimulated the activity of human 20S proteasome in a dose-dependent manner 
(Supplementary Information, Fig. 2S). Interestingly, three distinct activities of this multienzyme were differ-
ently stimulated. At 10 μM concentration of Blm-pep, ChT-L and PGPH activities increased around three times 
whereas T-L activity increased around seven-fold (Fig. 1). Surprisingly, Blm-pep did not influence any of the 
activities of yeast 20S proteasome at the concentrations sufficient to activate h20S.
To test the role of particular fragments of Blm-pep in human proteasome activation, we synthesized shorter 
analogs, consisting of 5, 6, 7, 9 and 11 amino acid residues (Table 1).
The ability of the tested analogs to stimulate ChT-L peptidase activity increased linearly with the length of the 
analog (Fig. 1A). Whereas Ac-5aa only slightly affected the activity of ChT-L (a 1.3-fold increase), the activity of 
Ac-11aa was only slightly lower than that observed for Blm-pep. Such a correlation between peptide length and 
capability to stimulate h20S was not observed for PGPH peptidase: all tested Blm-pep analogs, except for the 
shortest one (Ac-5aa), increased the activity of PGPH by around 2.5–3-fold, which is comparable to Blm-pep 
(Fig. 1B). The activation of T-L peptidase by the tested peptides was less consistent. Ac-6aa and Ac-7aa enhanced 
Figure 1. Activation of different proteolytic activities of the latent human 20S proteasome by Blm-pep and its 
acetylated analogs: (A) ChT-L, (B). PGPH, (C). T-L peptidase activity. The peptides concentration was 10 μM. 
Results are expressed as a percentage of activity of the latent human 20S proteasome. The variability of the data 
is presented as standard deviation error bars.
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the activity 2.5- and 4.5-fold, respectively, compared to almost 7-fold activation obtained with Blm-pep (Fig. 1C). 
Concomitantly, the longer fragments, Ac-9aa and Ac-11aa, both stimulated T-L activity only less than 3-fold.
All the above discussed Blm-pep fragments were acetylated to preserve peptide bond-like structure at their 
N-termini. To evaluate the influence of a free N-terminal amine group, present in the parent Blm-pep activator, 
we additionally tested three non-acetylated analogs. No influence of N-terminal acetylation was observed in 
the case of ChT-L activation (Supplementary Information, Fig. 3S). In the case of PGPH peptidase certain small 
differences between the activity of acetylated and nonacetylated peptides were noted, although they were not 
significant (Supplementary Information, Fig. 2S). In contrast to the above, acetylation significantly influenced 
the activation capability of certain peptides towards T-L peptidase (Fig. 2). The 9aa fragment was twice as potent 
as Ac-9aa in stimulating T-L activity. The opposite effect was observed for the 7aa peptide, whose activity was 
significantly lower compared to Ac-7aa. In the case of the eleven-residue fragment no influence of acetylation was 
observed on its capability to stimulate T-L peptidase.
Neither of the acetylated or nonacetylated analogs influenced the activity of yeast 20S proteasome, consistent 
with the lack of activity of Blm-pep towards this protease.
Structural basis of the Blm-pep-proteasome interaction. To elucidate the structural basis of the acti-
vating effect of Blm-pep we ventured to crystallize the peptide in a complex with both human 20S proteasome 
and yeast proteasome. Crystals were obtained for both proteins, however they diffracted sufficiently only in the 
second instance, despite significant optimization effort.
The crystal structure of the yeast proteasome:Blm-pep complex was determined at 3 Å resolution. The crys-
tals belonged to the P21 space group and contained a single proteasome molecule in the asymmetric unit. The 
structure was solved by molecular replacement using a model of yeast constitutive proteasome as a probe (PDB 
ID: 1RYP). The structure was refined with Rwork and Rfree values of 0.17 and 0.23, respectively, and was charac-
terized by decent geometry. The crystallographic data collection and refinement statistics are summarized in 
Supplementary Information Table 2S.
The electron density accounting for a part of the activator was clearly defined in two pockets, between α5 and 
α6 and, symmetrically, the α5′ and α6′ subunits, even prior to the introduction of the molecule into refinement 











Table 1. Sequences of Blm-pep and its shorter analogs. MS data are included in Supplementary Table 1S.
Figure 2. Stimulating potential of acetylated and non-acetylated Blm-pep analogs towards T-L peptidase of the 
latent human 20S proteasome. The peptides concentration was 10 μM. Results are expressed as a percentage of 
activity of the latent human 20S proteasome. The variability of the data is presented as standard deviation error 
bars.
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(10–14) of Blm-pep (Fig. 3A). The rest of the peptide is not defined by electron density, accounting for the flexi-
bility of this part and lack of stable interactions with the proteasome.
Blm-pep anchors deep into a pocket between the α5 and α6 proteasome subunits at the face of the channel 
gate (Fig. 3A). The C-terminus of Blm-pep is buried at the very bottom of the pocket and is stabilized by hydrogen 
bonds with the side chain amine of α6Lys62 and the main chain amides of α6Ser33 and α6Gly76. Ala14 is further 
stabilized by a hydrogen bond between its main chain amide and the α6Gly76 carbonyl. The main chain carbonyl 
of Tyr13 participates in one hydrogen bond - with α6Arg51, whereas its side chain provides multiple contacts, 
mainly through its hydroxyl group, which forms hydrogen bonds with the main chain nitrogen of α5Arg20, the 
main chain carbonyl of α5Gly19 and the side chain amide of α6Gln31. Both Tyr13 and Tyr12 also participate in 
hydrophobic interactions: Tyr13 with the side chain of α6Gln31, and Tyr12 with α5Leu28. Apart from this, the 
side chain hydroxyl of Tyr12 participates in a hydrogen bond with the α5Glu159 carboxylate. The main chain 
carbonyl of Ser11 is involved in a hydrogen bond with the hydroxyl group of α5Tyr165. The side chain of Arg10 
forms a salt bridge with α5Glu25. The main chain of Trp9 points out of the binding pocket into the solvent region, 
not contributing any interactions with either α5 or α6 subunits, and the side chain of this residue is already 
poorly defined by electron density and was not included in the final model. Such a binding mode is very closely 
followed in the two symmetrical pockets (the full list of the contacts at the both proteasome α faces is provided in 
Table 3S included in Supplementary Information). Further residues are not defined by electron density, suggest-
ing transient or no interaction with y20S.
The molecular details of Blm10 interaction with yeast proteasome have been elucidated previously4. Since 
Blm-pep was partially designed based on Blm10, it was interesting to compare the interactions of those two 
Figure 3. Interaction of Blm-pep with yeast 20S proteasome. (A) General localization of Blm-pep binding site 
between subunits α5 and α6 and detailed interactions guiding Blm-pep binding (blow-up). (B) Electron density 
defining Blm-pep fragment included in the model (2Fo-Fc omit map contoured at 1σ level). (C) Comparison of 
the binding modes of Blm-pep (green) and Blm10 (blue) at the surface of yeast 20S proteasome (the difference 
in interaction of both activators with Q60 is highlighted).
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molecules with yeast proteasome. Blm-pep binds at the same α5/α6 intersubunit pocket as the C-terminal part of 
Blm10, however the interactions guiding the affinity of the two molecules remain considerably different (Fig. 3C). 
The ultimate alanine residue is oriented almost identically in both structures and its affinity is guided by the same 
primary canonical interaction of the terminal carboxyl group and the side chain amine of α6Lys62 and backbone 
amides of α6Ser33 and α6Gly76, further stabilized by the interaction of the backbone amide and the carbonyl 
oxygen of α6Gly76. The overall disposition of the penultimate tyrosine residue and the interactions provided by 
its side chain are comparable in both structures, but the binding of the backbone is already guided by different 
interactions. In Blm10 the backbone carbonyl participates in a hydrogen bond with the side chain of α6Gln60, 
whereas such an interaction is not observed in the structure containing Blm-pep, due to the different disposition 
of the side chain of α6Gln60. Beyond the penultimate tyrosine, the disposition and, consequently, the interactions 
involving Blm10 and Blm-pep are completely different in the two structures (Fig. 3C). In particular, Blm-pep 
does not follow the β-sheet-like hydrogen bond pattern observed in Blm10. Overall, despite the fact that the 
C-terminal part of Blm-pep was designed based on Blm10, the binding modes of the two activators differ quite 
considerably.
Upon binding of Blm10 the proteasome β-subunits do not move substantially (RMSD 0.4 Å), but the 
α-subunits move somewhat to form a partially open entrance pore4. In the structure of the y20S:Blm-pep com-
plex the enzyme is found in its closed conformation, which supports the fact that Blm-pep failed to activate y20S. 
Nevertheless, local alignment of the Cα atoms of the β-rings of our structure with that of the modulator-free 
y20S results in RMSD values of 0.6 Å and 0.9 Å for the β- and α-rings, respectively. The progressive increase 
in RMSD from the core region to the distal ends of the proteasome indicates that although Blm-pep binding 
does not induce gate opening it causes small changes in the architecture of the α-ring, presumably resembling 
the initial stages of gate opening. Such a small change can be detected in the position of the highly conserved 
Tyr123-Gly124-Gly125 loop, which is a key element of the aperture (α-annulus) restricting the access of sub-
strates to the catalytic center in the latent proteasome42. Upon Blm-pep binding this loop shifts more than 1 Å, 
which results in breaking of a hydrogen bond between the Gly124 carbonyl and the hydroxyl group of Ser13 
(Fig. 4). Since Blm-pep binds to 20S in two copies only, this shift is limited to the α6/6′ subunits and does not 
cause a rotation propagating around the whole α-ring, as it was observed in archeal 20S interacting with PAN 
peptides43. Nevertheless, the Blm-pep:y20S complex is characterized by a conformation which can be called the 
intermediate between that of the free – closed, and partially opened proteasomes.
Model of Blm-pep:h20S interaction. Despite great effort, we were unfortunately unable to obtain crystals 
of sufficient quality to determine the structure of human proteasome with Blm-pep. However, the α5/α6 pockets 
in yeast and human enzymes show enough similarity to allow creation of a sensible model of Blm-pep:h20S inter-
action. In fact, the only differences at the binding site include α5Leu28 which is substituted by Ile in h20S, and 
α6Ala78 which is Thr in h20S. Therefore, we constructed an interaction model by docking Blm-pep, extracted 
from our experimental structure, to the experimental structure of human constitutive 20S proteasome (PDB ID: 
4R3O), and minimizing the interaction energy.
Our model allows us to conclude that interactions of Blm-pep at the α5/α6 pocket of yeast and human 
proteasome should be largely similar, although some minor differences are also noted (Fig. 5). In both com-
plexes Arg10 forms a salt bridge with α5Glu25. The interactions of Tyr12 with α5Leu28/α5Ile28 and α5Glu159/
α5Asp157, respectively, in yeast/human proteasome, are comparable in their nature. In addition, the interactions 
of Tyr13 with α5Arg20, α6Arg51 and α5Gly19 are conservative in both yeast and human proteasomes. The salt 
bridge of the C-terminal carboxylate of Blm-pep and α6Lys62 is again conservative, as are two further hydro-
gen bonds connecting the carboxylate with the backbone of α6Ser33 and α6Gly76. However, the interaction of 
the C-terminal carboxylate with the side chain of α6Ser33 is possible only in the human proteasome. The latter 
hydrogen bond constitutes the only apparent difference in the binding modes of Blm-pep in the α5/α6 pocket of 
human and yeast proteasomes.
Figure 4. Distal conformational change of the 20S induced by binding of Blm-pep. The change involves the 
highly conserved loop, which is a part of the α-annulus regulating the substrate access to the catalytic center. 
Color coding is as follows: grey - latent proteasome (1RYP); beige – the proteasome bound to Blm-pep.
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Discussion
Efficient activators of human 20S proteasome might alleviate the deleterious consequences of certain pathogenic 
states by stimulating degradation of damaged proteins and preventing their aggregation into toxic oligomers. 
Such a strategy could potentially find utility in treatment of Parkinson’s and Huntington’s diseases20, 21 or man-
agement of oxidative stress consequences22–24. Nevertheless, development of proteasome activators is hindered by 
insufficient structural understanding of the activation process. To facilitate the design of proteasome modulators 
we determined the structure of the y20S proteasome in a complex with Blm-pep, a peptide capable of stimulating 
the three proteolytic activities of human 20S. This crystal structure demonstrates for the first time the mode of 
binding of a low molecular weight activator at atomic resolution. All previously available information on protea-
some activation was either based on proteinaceous activators or did not reach high resolution and indicated only 
the sites at which an activator had been found, which did not enable detection of its specific interactions with the 
proteasome.
Our structure revealed that Blm-pep occupies a single site at each proteasome α-ring and defined the molec-
ular details of the interaction. The binding pocket is located between the α5/α6 subunits. The same pocket is 
occupied by the C-terminus of Blm104, a proteinaceous activator on which we based the design of our pep-
tide activator. Interestingly, the overall interactions guiding the affinity of Blm-pep and Blm10 are not identi-
cal, despite both molecules sharing the C-terminal sequence responsible for their anchoring to the proteasome 
α-ring. Moreover, Blm10 induces a partially open conformation of the entrance pore whereas the pore is closed in 
the structure of the complex of y20S with Blm-pep. Such an observation is corroborated by the fact that Blm-pep 
was unable to activate the proteolytic activity of yeast proteasome. Nevertheless, the closed conformation of the 
proteasome in the complex with Blm-pep is not identical to the closed conformation of the unliganded pro-
teasome. In fact, it may be described as an intermediate between the unliganded and Blm10-bound structure. 
This indicates that although binding of the HbYX motif at the α-ring may be necessary for induction of an open 
conformation, as demonstrated by others6, 13, 44, single HbYX motif binding is not sufficient, and only induces an 
intermediate, but still closed conformation. It now seems clear that there must be secondary interactions which 
help Blm10 to partially open the gate. In dissecting the interface between Blm10 and 20S we found another 
region in the proteasome α-face which is in close contact with the activator. It encompasses the N-termini of the 
α-subunits, which in the unliganded proteasome pack tightly against each other, stabilizing the closed confor-
mation. In the crystal structure of the proteasome complex with Blm10, only the α5 and α6 N-termini – which 
create the pocket hosting the binding motif4, 37 – are clearly defined in the electron density maps. These N-termini 
apparently reorient upon ligand binding, pointing upwards into the cavity within the ligand body (Fig. 4S). 
Conformation of the α5 and α6 subunits is stabilized due to a number of contacts with the ligand residues, other 
than its C-terminal HbYX (Table 4S). This new finding about the possible importance of secondary interactions 
requires the classical model of proteasome activation to be revisited. It had been believed thus far that proteasome 
activation by a protein partner possessing a singular HbYX motif is driven by binding of this motif at the inter-
subunit pocket, thereby reorienting the Pro17 reverse turn and inducing the open conformation of the gating 
pore. In the light of the above discussed data it is more probable that binding of a single HbYX motif induces a 
pre-open state, but is insufficient to result in sustained gate opening. Only secondary interactions outside the α 
pocket would stabilize a fully open conformation in the case of monomeric activators (Fig. 6, right).
It has been demonstrated that the HbYX motif-holding C-terminal peptide derived from PAN stimulates 
proteasome activity by inducing an open conformation of the entrance gate of T. acidophilum proteasome43. 
Figure 5. Comparison of Blm-pep interaction with yeast and human proteasome. Left – structure of yeast 20S 
proteasome (α5 and α6 are colored beige and gray, respectively) in complex with Blm-pep (green), determined 
in this study (5NIF). Interacting residues within the proteasome are highlighted blue. Right – modeled 
interaction of Blm-pep with human 20S proteasome (model based on 4R3O; orientation and colour coding 
same as in the left panel). The hydrogen bond distinguishing the interactions of Blm-pep with yeast and human 
20S is shown (see text).
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This, however, does not contradict our conclusions since the α-ring of archeal proteasome is build of identical 
subunits and therefore the peptide activator may bind in all seven pockets. In eukaryotic proteasomes α-subunits 
are not identical and y20S binds Blm-pep at only a single site. We hypothesize that in the case of small activators, 
such as Blm-pep, in which interactions at secondary sites are unlikely, only a collaborative effect of interactions 
at multiple sites is capable of sufficiently stabilizing the open conformation (Fig. 6, center). Such a hypothesis is 
corroborated by the fact that two different C-terminal peptides of the 19S regulator show a cooperative effect: 
while Rpt5 is able to activate the proteasome, conjoint additon of Rpt2 increases the activity several times45. Our 
hypothesis is further supported by the recently published cryo-EM structure of the 19S:h20S complex, which 
showed a closed conformation of the entrance pore despite the C-termini of two HbYX-holding subunits of 
19S regulator being found deeply immersed in the enzyme’s intersubunit pockets11. Moreover, in a similar 3D 
reconstruction of yeast 26S, binding of three HbYX-possessing subunits of 19S was also insufficient to render 
the gate permanently opened12. Concomitantly, in the cryo-EM structure of T. acidophilum proteasome soaked 
with a 7-residue peptide derived from the C-terminal sequence of PAN, the structural organization of the gating 
pore was different and the entrance pore notably wider than in the closed form43. In this structure, however, the 
ligand molecules were found in all seven pockets of the α-ring, and also in all seven proteolytic sites located in the 
β-ring. Although direct demonstration is still necessary, all these results advocate that only concominant action 
of multiple HbYX motif-containing peptides may result in a fully open conformation and therefore an efficient 
activator must occupy more then a single intersubunit pocket. Alternatively, the activator must provide second-
ary interactions with the gating residues. Such a conclusion has important implications for the design of novel 
activators which must be flexible enough to overcome interpocket variance present in the eukaryotic proteasome.
Although Blm-pep is quite an efficient stimulator of human 20S peptidases it did not display capability to 
activate the yeast proteasome. A similar lack of activating power has been detected by Dange et al. in the case of 
an 8-residue peptide derived from the C-terminal sequence of Blm10, which did not activate the ChT-L peptidase 
of y20S40. It was also reported that this peptide stimulated T-L and PGPH activities, but this was not the case 
for Blm-pep, which did not show any activating potency toward the yeast enzyme peptidases. We do not know, 
however, what concentration of a modulator was used in the studies of Dange et al. since this information was not 
disclosed in their paper.
Our hypothesis on the collaborative action of small molecule activators might explain why Blm-pep activates 
only human 20S proteasome, but not its yeast ortholog. Comparison of the intersubunit pockets of both enzymes 
demonstrates that some pockets of the yeast proteasome are less spacious than their human counterparts and 
may be more selective and exclude some ligands. Thus, it is possible that a lack of opportunity for collaborative 
action of activator molecules is responsible for the fact that Blm-pep does not activate yeast 20S proteasome, 
although it activates its closely related human ortholog. It is also of note that the assymetric α-ring of eukaryotic 
proteasomes renders the α2, α3, α4 and to a lesser extent α5 subunits special positions in closing the entrance to 
the catalytic chamber46. Binding of activator molecules in the pockets created by these subunits may be an indis-
pensable element of the proteasome activation mechanism. The pockets located between these subunits are empty 
in our closed-gate structure. In the structures of 19S regulator with human or yeast 20S, in which the proteasome 
gate is also closed, only the α1/α2 and α5/α6 pockets, or the α1/α2, α3/α4 and α5/α6 pockets, are occupied, 
respectively11, 12. In contrast, in the PA26:y20S complex, in which the electron density of PA26 C-termini were 
detected in α2/α3, α3/α4, α4/α5 and α5/α6 pockets, the proteasome gating pore is fully open37. In addition, in 
the s4 proteolytic state of y26S, described by Wehmer et al., the gate was found open when the fourth – α2/α3 – 
intersubunit pocket became involved in interactions with Rpt subunits of the 19S regulator, joining the α1/α2, 
α3/α4 and α5/α6 pockets, which are occupied in the closed and pre-open conformations of the s1-s3 states12.
Only 5 residues of Blm-pep are defined by electron density in our structure, and they are located at the 
α-pocket of the proteasome. At the same time, longer variants of Blm-pep demonstrated higher activity compared 
to shorter ones. This suggests that the extended N-terminal part of Blm-pep provides additional transient inter-
actions at the gating channel. Moreover, the fact that the influence of N-terminal acetylation on the compound 
activity depends on the length of the activator further advocates the presence of transient interactions within 
Figure 6. Revisited model of proteasome activation supporting all currently available data. Binding of a sigle 
HbYX motif is not sufficient to allow substrate access. Only interaction at multiple HbYX binding sites or at a 
single site together with secondary interactions allow for efficient proteasome activation.
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the N-terminal part. Interactions of the basic N-terminal amine group may help in initiation of gate opening, on 
condition, however, that it reaches a suitable partner. If not, it may even obstruct positive conformational changes, 
disabling activation of the proteasome, which we observed in the case of the 7aa analog as compared to Ac7aa 
(Fig. 2). Such transient contacts, even if present, are not amenable to crystallographic analysis and are highly 
speculative at this point.
In conclusion, we have characterized the structural basis of the interaction of a low molecular weight protea-
some activator with the target protease, facilitating rational design of more drug-like activators. Our hypothesis 
on the collaborative function of intersubunit pockets in proteasome activation may have important implications 
for the design of pharmacologically relevant molecules, though this still requires better experimental validation.
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